Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Rafael Holdings narrows losses but faces long timelines to value from its drug pipeline.

What the company is saying

Rafael Holdings highlights the submission of a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™) targeting Niemann-Pick Disease Type C, emphasizing regulatory progress as a core milestone. The company acknowledges that the pivotal Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, but stresses a 71% slowing of disease progression in a prespecified subgroup on background miglustat and/or leucine therapy. The NDA includes a request for a rare pediatric disease priority review voucher, indicating a strategy to accelerate review and potentially monetize the voucher. The announcement also points to a new exclusive worldwide license from MIT for hydroxypropyl-β-cyclodextrin in Alzheimer’s disease, and the launch of a Phase II trial of Promitil® in Israel. Rafael Medical Devices is expanding U.S. commercialization of the FDA-cleared VECTR™ System. Management attributes the year-over-year reduction in net loss primarily to lower general and administrative expenses, including payroll, stock-based compensation, and professional fees, while acknowledging higher R&D costs due to the consolidation of Cyclo Therapeutics.

What the data suggests

As of July 31, 2026, Rafael Holdings had $22.1 million in cash and cash equivalents and total assets of $83.1 million against total liabilities of $11.1 million. For the fiscal year ended July 31, 2026, the company reported a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, an improvement from a $30.5 million loss, or $1.04 per share, in the prior year. The improvement was driven by a $4.4 million gain on settlements and the absence of prior-year unrealized losses on Cyclo investments, offset by a sharp rise in research and development expenses to $24.3 million from $12.8 million, largely due to a $13.4 million increase in Cyclo’s R&D spend. General and administrative expenses fell to $9.7 million from $13.8 million, with reductions in professional fees ($1.3 million), stock-based compensation ($1.2 million), and payroll ($0.6 million). Quarterly revenues remain minimal at $244,000 for the last quarter and $874,000 for the year, underscoring the company’s pre-commercial status. The NDA for remibetadex is supported by a Phase 3 study that failed its primary endpoint but showed benefit in a subgroup, introducing regulatory uncertainty. The company is actively investing in pipeline and device commercialization but has not yet demonstrated revenue traction from these efforts.

Analysis

The announcement is measured in tone and provides detailed, transparent financial and operational disclosures. Most claims are realised and supported by concrete data, such as the NDA submission, clinical trial completions, licensing agreements, and financial results. The only forward-looking claim of note is the request for a rare pediatric disease priority review voucher, which is a standard regulatory step and not presented with exaggerated language. The company is incurring significant R&D and commercial build-out expenses, with only modest revenues and ongoing net losses, indicating a long execution distance before potential profitability. However, the language does not overstate progress or inflate expectations; it accurately reflects the current status and challenges. There is no evidence of narrative inflation or overstatement.

Risk flags

• ●Regulatory risk is elevated as the NDA for remibetadex is based on a Phase 3 trial that did not meet its primary endpoint in the overall population, which may challenge FDA acceptance or approval and delay or prevent commercialization.
• ●Financial risk persists due to ongoing net losses ($29.6 million for the year), limited revenues ($874,000 for the year), and a cash balance of $22.1 million, which may not be sufficient if regulatory or commercial milestones are delayed.
• ●Execution risk is present in the commercial build-out of the VECTR™ System and the integration of new pipeline assets, as there is no evidence of significant revenue generation or market adoption to date.
• ●Pipeline concentration risk is apparent, as the company’s lead asset is subject to regulatory uncertainty and the rest of the pipeline is at earlier stages, increasing dependence on a single near-term catalyst.
• ●R&D expense risk is notable, with research and development spend nearly doubling year-over-year to $24.3 million, driven by Cyclo consolidation, which could pressure cash reserves if not matched by future funding or revenue.

Bottom line

Rafael Holdings has narrowed its net loss year-over-year, primarily by cutting general and administrative expenses, but continues to post substantial losses as it invests heavily in R&D and pipeline expansion. The NDA submission for remibetadex is a key milestone, but regulatory approval is uncertain given the Phase 3 trial’s failure to meet its primary endpoint in the overall population. Cash reserves of $22.1 million provide some runway, but with minimal revenues and high ongoing expenses, additional funding may be required if value-creating milestones are delayed. Commercialization of the VECTR™ System and new pipeline assets are at early stages, with no evidence of material revenue impact yet. The most important takeaway is that while the company is making progress on regulatory and operational fronts, the timeline to meaningful value realization remains long and is subject to significant regulatory and financial risks. Investors should focus on FDA feedback for remibetadex and evidence of commercial traction in the coming quarters.

Announcement summary

(NYSE:RFL) Rafael Holdings, Inc. reported financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026. On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™) for Niemann-Pick Disease Type C, supported by the Phase 3 TransportNPC™ study completed in June 2026. The Phase 3 study did not meet its primary endpoint in the overall population (p=0.19), but a prespecified subgroup analysis showed 71% slowing of disease progression in patients receiving background miglustat and/or leucine therapy (p=0.046). The NDA includes a request for a rare pediatric disease priority review voucher. In April 2026, Cyclo entered into an exclusive, worldwide license with the Massachusetts Institute of Technology for hydroxypropyl-β-cyclodextrin in Alzheimer’s disease. In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in cisplatin-ineligible head and neck cancer patients was launched in Israel. Rafael Medical Devices continued the U.S. commercial build-out of the FDA-cleared VECTR™ System and its regional distributor network. As of July 31, 2026, Rafael Holdings had cash and cash equivalents of $22.1 million. For the three months ended July 31, 2026, the company recorded a net loss attributable to Rafael Holdings of $9.2 million, or $0.18 per share, compared to a net loss of $12.1 million, or $0.28 per share, in the prior year period. Research and development expenses were $7.5 million for the three months ended July 31, 2026 and 2025. General and administrative expenses were $2.4 million for the three months ended July 31, 2026, compared to $5.5 million in the prior year. For the twelve months ended July 31, 2026, net loss attributable to Rafael Holdings was $29.6 million, or $0.58 per share, versus $30.5 million, or $1.04 per share, in the prior year. The year-over-year decrease in net loss reflects a $4.4 million gain on Cornerstone’s settlements of accounts payable and convertible notes payable and the absence of prior-year unrealized losses on the investment in Cyclo, partially offset by higher R&D expenses following the consolidation of Cyclo Therapeutics in March 2025. Research and development expenses were $24.3 million for the twelve months ended July 31, 2026, compared to $12.8 million in the prior year, with the increase primarily due to a $13.4 million rise in Cyclo’s R&D expenses and a $0.4 million increase in R&D stock-based compensation, offset by decreases in R&D payroll of $1.5 million and clinical trial and other expenses of $0.8 million. General and administrative expenses were $9.7 million for the twelve months ended July 31, 2026, compared to $13.8 million in the prior year, with the $4.1 million decrease primarily due to reductions in professional fees of $1.3 million, stock-based compensation of $1.2 million, payroll expense of $0.6 million, and other expenses. As of July 31, 2026, total assets were $83,055,000 and total liabilities were $11,085,000. Revenues for the three months ended July 31, 2026 were $244,000, and for the twelve months ended July 31, 2026 were $874,000. Weighted average number of shares used in the calculation of loss per share for the year ended July 31, 2026 was 51,393,118.

Disagree with this article?